Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Thu, 15.07.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, July 15, 2021
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
Company Announces Successful Completion of Tender OfferMoves Forward with Strategic Funding Partnership with Royalty Pharma
MorphoSys AG (FSE: MOR; NASDAQ: MOR [ … ]
Thu, 01.07.2021
MorphoSys AG
Media ReleaseMorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Cons [ … ]
Fri, 25.06.2021
MorphoSys AG
Media Release
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the [ … ]
Wed, 16.06.2021
MorphoSys AG
Media Release
MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) ("Constellation") for $34.00 per sha [ … ]
Fri, 04.06.2021
MorphoSys AG
Media ReleaseMorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, Mass., USA and WILMINGTON, Del., [ … ]
Wed, 02.06.2021
MorphoSys AG
MorphoSys to Acquire Constellation Pharmaceuticals
Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209
Bolsters Position in Hematology-Oncology and Expands into Solid Tumors
Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability to Provide New Cancer T [ … ]
Wed, 02.06.2021
MorphoSys AG
Ad hoc release according to article 17 para. 1 MAR
Planegg/Munich, Germany and Cambridge, Mass., June 2, 2021
Ad hoc: MorphoSys to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys"), announces today that it has entered into a definitive agreemen [ … ]
Fri, 21.05.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 21, 2021
MorphoSys To Participate in UBS Global Healthcare Conference
MorphoSys AG (FSE & NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday May 25, 2021 at 7:00 a.m. E [ … ]
Wed, 19.05.2021
MorphoSys AG
Media ReleaseMorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting
PLANEGG/MUNICH, Germany - May 19, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annua [ … ]
Tue, 11.05.2021
MorphoSys AG
Media ReleaseMorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
PLANEGG/MUNICH, Germany and WILMINGTON, Del., USA - May 11, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first pat [ … ]